Blog Full Right Sidebar

India’s IPO market faces potential disruptions as several companies risk missing their listing deadlines due to a market downturn. Firms like Credila Financial Services and Dorf-Ketal Chemicals are among those with approvals nearing expiry. Valuation concerns and weak secondary market performance are prompting companies to delay or refile, impacting the IPO pipeline after two strong years.Read More

Vachana Investments MD CA Rudramurthy BV advises Indian equity investors to view market rallies as shorting opportunities until Brent crude falls below $95, the rupee drops below 92, and the VIX cools under 15. He emphasizes preserving capital and suggests hedging long-term portfolios with put options, identifying Havells and Lodha as specific short trade recommendations.Read More

Indian drug maker Sun Pharma faces significant exposure to potential US tariffs on medicines. Global brokerage Jefferies warns that while generics may be exempt, Sun Pharma’s specialty and innovative products, manufactured in countries like South Korea and the EU, could face levies up to 15%. The US administration is reportedly preparing these tariffs, with an announcement possibly today.Read More

Global markets saw sharp volatility in March as the Iran war and a surge in crude oil prices reshaped investor expectations. Aswath Damodaran said the selloff reflected recalibration, not panic. Rising inflation expectations, higher bond yields and modest risk repricing drove equities lower amid continued uncertainty over the conflict’s trajectory.Read More

Indian stock markets experienced significant volatility on Thursday, with a sharp crash triggered by US President Trump’s comments on Iran. Despite an initial plunge of over 1,600 points for Sensex and 500 points for Nifty 50, both indices ultimately closed higher for the second consecutive session, marking marginal gains.Read More